Immunohistochemical localization of prolactin in functioning and regressing corpus luteum of pituitary autotransplanted rats.
In an attempt to shed light on the intimate mechanism by which prolactin (PRL) switches from supporting corpus luteum (CL) progesterone secretion (P) to promote structural regression of the CL, day 2 (metestrous) autopituitary transplanted (APTr) rats were used. In APTr rats the CL is under the only control of PRL since an almost complete absence of LH and FSH exist. The experimental group was given bromocriptine (CB-154: 0.4 mg/day) on days 12, 13 and 14 of the cycle and 0.25 ml of ethanol from day 15 to day 21. The control group was given CB-154 from day 12 to day 21. Rats were hemiovariectomized on day 12 to assess the morphological characteristics of the active CL. PRL and P were determined by RIA on days 12, 15 and 22. On day 12, both PRL and P levels were higher than 80 ng/ml (luteotrophic action of PRL). On day 15, due to treatment with CB-154, the levels of both hormones had fallen below 7 ng/ml (functional luteolysis). On day 22, PRL levels were again high (greater than 50 ng/ml) in the shortly CB-154-treated rats and low (less than 5 ng/ml) in the controls; the P levels were lower than 5 ng/ml in both groups. PRL-induced structural luteolysis in the experimental group (hyperprolactinemic) was assessed by the structural characteristics and by the CL weight loss on day 22 in comparison with that exhibited by control rats. The immunohistochemical staining of both endogenous and total PRL in the lutein cells showed that the internalization of PRL is not modified by the functional state of the CL, nevertheless the intracellular redistribution of the internalized hormone varied in relation with the PRL action on the CL (luteotrophic, day 12 vs luteolytic, day 22). These results seem to indicate that intracellular mechanisms rather than receptor content determine CL response to PRL.
Martín de las Mulas
J
J
Department of Pathology, Faculty of Medicine, University of Córdoba, Spain.
Aguilar
E
E
Sánchez-Criado
J E
JE
D000818:Animals; D001971:Bromocriptine / Q000008:administration & dosage; D003338:Corpus Luteum / Q000502:physiology* / Q000648:ultrastructure; D005260:Female; D007150:Immunohistochemistry; D008184:Luteal Cells / Q000737:chemistry*; D003341:Luteolysis / Q000187:drug effects / Q000502:physiology*; D009929:Organ Size; D010053:Ovary / Q000502:physiology; D010902:Pituitary Gland / Q000737:chemistry / Q000502:physiology*; D011374:Progesterone / Q000032:analysis / Q000097:blood; D011388:Prolactin / Q000032:analysis / Q000097:blood / Q000502:physiology*; D051381:Rats; D011919:Rats, Inbred Strains
D001971:Bromocriptine; D011374:Progesterone; D011388:Prolactin